All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Watch on TikTok

TikTok claims FDA approved orforglipron - that's wrong

NUTRI Letícia Boettcher R.

TikTok creator

20.0K viewsWatch on TikTok →

Quick answer

Orforglipron is an experimental oral GLP-1 receptor agonist in Phase 2 development by Eli Lilly. Early results show 12.6% weight loss over 36 weeks, but the drug has not received FDA approval and is years away from market availability.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion
Start provider reviewReview Compounded Tirzepatide

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For TikTok claims FDA approved orforglipron - that's wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialSemaglutide evidence2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.

PubMed

Randomized trialSemaglutide evidence2021

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance

Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.

PubMed

Randomized trialTirzepatide evidence2022

Tirzepatide Once Weekly for the Treatment of Obesity

Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.

PubMed

Randomized trialTirzepatide evidence2024

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction

Used for continuation, stopping, and maintenance questions after initial weight loss.

PubMed

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Start the provider review

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Helpful context before the funnel

Tirzepatide video claims video hub

Compare nearby social claims before acting.

Review Compounded Tirzepatide

Move from claim context to product, safety, and access details.

Review method

See how FormBlends checks viral health claims.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

View topic hubTirzepatide video claimsReview TirzepatideTreatment or product pathCompare GLP-1 optionsDeeper FormBlends guide

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "TikTok claims FDA approved orforglipron - that's wrong" from NUTRI Letícia Boettcher R.. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Orforglipron is an experimental oral GLP-1 receptor agonist in Phase 2 development by Eli Lilly.

The reason this review is not generic is the source wording and the canonical claim label "glp1 essa semana foi liberado pelo fda orfoglipron um novo med." In this clip, the useful excerpt is: "Essa semana foi liberado pelo FDA Orfoglipron!" That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Phase 2 trials showed 12.
People who land here are usually trying to understand whether the Compounded Tirzepatide claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Orforglipron is an experimental oral GLP-1 receptor agonist in Phase 2 development by Eli Lilly.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Orforglipron is an experimental oral GLP-1 receptor agonist in Phase 2 development by Eli Lilly. Early results show 12.6% weight loss over 36 weeks, but the drug has not received FDA approval and is years away from market availability.
  • Orforglipron has not been approved by the FDA and remains in early clinical development
  • Phase 2 trials showed 12.6% weight loss with orforglipron over 36 weeks, less than tirzepatide's 20.9% in 72 weeks

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • Orforglipron has not been approved by the FDA and remains in early clinical development
  • Phase 2 trials showed 12.6% weight loss with orforglipron over 36 weeks, less than tirzepatide's 20.9% in 72 weeks
  • The drug's main advantage would be oral administration versus weekly injections for current GLP-1 medications
  • No studies have tested orforglipron for weight maintenance after other GLP-1 treatments
  • Phase 3 trials are expected to begin in 2024, meaning FDA approval is likely years away
  • Currently approved GLP-1 alternatives to Mounjaro include semaglutide and liraglutide
  • People typically regain two-thirds of lost weight within a year of stopping GLP-1 treatment

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this TikTok video claim?

Nutritionist @nutriletiboettcher tells her 20,000 viewers that "this week the FDA released orforglipron," calling it a new GLP-1 receptor agonist that could be a good alternative for weight maintenance after using Mounjaro (tirzepatide).

She's positioning orforglipron as an already-available treatment option. The timing matters here because people are actively looking for Mounjaro alternatives due to supply issues and cost concerns.

Did the FDA actually approve orforglipron this week?

No, and this is a significant error. The FDA has not approved orforglipron for any indication. What actually happened was Eli Lilly released positive Phase 2 trial results for orforglipron in December 2023, showing 12.6% weight loss at the highest dose over 36 weeks.

Orforglipron is still in clinical development. Lilly expects to start Phase 3 trials in 2024, meaning FDA approval is likely years away, not this week.

This isn't a small mistake about timing. It's telling people a drug is available when it isn't.

What do we actually know about orforglipron's effectiveness?

The Phase 2 GIPR-027 study (not yet published in a peer-reviewed journal) found orforglipron led to placebo-adjusted weight loss of 9.4% at 24mg once daily and 12.6% at 45mg once daily over 36 weeks.

That's decent but not spectacular. For comparison, the SURMOUNT-1 trial found tirzepatide (Mounjaro) produced 20.9% weight loss at 15mg over 72 weeks.

Orforglipron's main advantage isn't superior effectiveness. It's that it's an oral pill, while current GLP-1 drugs require weekly injections.

Could orforglipron work for weight maintenance after Mounjaro?

This is pure speculation at this point. No studies have tested orforglipron specifically for weight maintenance after other GLP-1 drugs, and the creator provides no evidence for this claim.

We know from other GLP-1 research that people typically regain weight when they stop treatment. The STEP 1 extension study showed people regained about two-thirds of their lost weight within a year of stopping semaglutide.

Whether switching from injectable tirzepatide to oral orforglipron would maintain weight loss is an unanswered question that won't be resolved until we have head-to-head studies.

What should people actually know about GLP-1 alternatives?

If you're looking for alternatives to Mounjaro right now, your options are limited to currently approved medications like semaglutide (Wegovy, Ozempic) or liraglutide (Saxenda).

Don't make treatment decisions based on drugs that aren't available yet. Orforglipron might reach the market in 3-5 years if Phase 3 trials go well and the FDA grants approval.

The promise of an oral GLP-1 drug is real, but it's not ready for patients today.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

NUTRI Letícia Boettcher R. · TikTok creator

20.0K views on this video

Essa semana foi liberado pelo FDA Orfoglipron!!! Um novo medicamento que se liga ao receptor de glp1 e nos estudos mostra ser uma ótima alternativa de manutenção de peso pós Mounjaro!

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about orforglipron has not been approved by the fda?

Orforglipron has not been approved by the FDA and remains in early clinical development

What does the video say about phase 2 trials showed 12.6% weight loss with?

Phase 2 trials showed 12.6% weight loss with orforglipron over 36 weeks, less than tirzepatide's 20.9% in 72 weeks

What does the video say about the drug's main advantage would be?

The drug's main advantage would be oral administration versus weekly injections for current GLP-1 medications

What does the video say about no studies have tested?

No studies have tested orforglipron for weight maintenance after other GLP-1 treatments

What does the video say about phase 3 trials?

Phase 3 trials are expected to begin in 2024, meaning FDA approval is likely years away

What does the video say about currently approved glp-1 alternatives to mounjaro include semaglutide?

Currently approved GLP-1 alternatives to Mounjaro include semaglutide and liraglutide

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by NUTRI Letícia Boettcher R., not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.